Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt

Werewolf Therapeutics, Inc.

2026-Q1 EPS reported -$0.28

Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.
Net loss of $13.5M for Q1 2026, improved from $18.1M loss in Q1 2025.
R&D expenses $8.2M (down from $13.1M YoY); G&A expenses $5.1M (up from $4.9M).
Entered asset purchase agreement with Jazz Pharmaceuticals for JZP898 (IFNα program); repaid all K2 loan obligations as of May 6, 2026.
Company continues to evaluate strategic alternatives with Piper Sandler; cash runway guidance to be updated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $13.5 million for the first quarter of 2026.

Period: first quarter ended March 31, 2026
Net income: Net loss was $13.5 million for the first quarter of 2026
Result: reported results

Exact text from the filing

Net loss was $13.5 million for the first quarter of 2026, compared to $18.1 million for the same period in 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.